Bioactive Glass vs Bone Grafts After Curettage of Benign Bone Tumors
Can bioactive glass replace bone grafts after curettage of benign bone Tumors? A systematic review and meta-analysis of randomized controlled trials.
J Orthop . 2025 Jun 3:69:208-215.Four randomized controlled trials including 156 patients with benign bone tumors were analyzed in this systematic review and meta-analysis comparing bioactive glass (BAG) to autografts or allografts following curettage. Pooled outcomes of interest included recurrence, overall complications, mild complications, and reoperations. Recurrence rates were similar between BAG (18.7%) and bone grafts (21.0%), as were overall complications, mild complications, and reoperations. Subanalysis of ≥2-year follow-up yielded consistent results. These findings suggest that BAG performs comparably to traditional bone grafts and may be a viable alternative after curettage for benign bone tumors.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
